Women represent an increasing proportion of HIV cases globally and in Canada, yet are
underrepresented in clinic trials. It is therefore critical to conduct this study on
antiretroviral (ARV) pharmacokinetics (PK) in women to obtain additional information on ARV
drug levels in women and their relation to adverse events (AEs).
The hypothesis for this study is three-fold:
1. that the mean drug levels (Cmin and Cmax) of ARVs will be significantly higher in our
female population as compared to the mean drug levels in the historical HIV population
(which is primarily men)
2. that ARV drug levels, particularly Cmin, are associated with body weight in women
3. that higher ARV drug levels, particularly Cmax, are associated with higher frequency and
severity of AEs.
The objectives of this study are as follows:
Primary objectives:
1. To demonstrate that levels of Protease Inhibitors (PIs) and Non-Nucleoside Reverse
Transcriptase Inhibitors (NNRTIs) are significantly higher in our female population as
compared to the mean drug levels in the historical general population (which is
primarily men).
2. To determine the association between PI and NNRTI minimum concentration (Cmin) and body
weight in our female population.
Secondary objectives
1. To determine the association between maximum concentration (Cmax) and the frequency and
severity of AEs as measured by the proportion of patients with grade 2 or higher
laboratory or clinical AEs and the Symptom Index Score in women.
2. To determine the association between ARV drug levels and age, race, height, body mass
index, adherence, hormonal levels and therapy, menstruation history, duration of HIV
infection, duration on ARV therapy, baseline viral load, baseline CD4 count, present CD4
count, hepatitis B or C infection, class of ARVs, presence of ritonavir and other
medications.